U01 DK107013/DK/NIDDK NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2014	1
2015	5
2016	3
2017	12
2018	17
2019	15
2020	17
2021	9
2022	8
2023	7
2024	7
2025	17
2026	5

1

Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention.

You L, Parikh HM, Triolo TM, Ferrat LA, Templeman EL, Oram RA, Gottlieb PA, Rich SS, Onengut-Gumuscu S, Steck AK, Krischer J, Redondo MJ. You L, et al. Diabetes Care. 2026 Feb 1;49(2):344-351. doi: 10.2337/dc25-2006. Diabetes Care. 2026. PMID: 41364459 Free PMC article.

2

Genetic Risk and Transition Through Preclinical Stages of Type 1 Diabetes.

Steck AK, Parikh HM, Triolo TM, Ferrat L, You L, Gottlieb PA, Oram RA, Onengut-Gumuscu S, Krischer JP, Rich SS, Redondo MJ. Steck AK, et al. J Clin Endocrinol Metab. 2026 Jan 21;111(2):e493-e499. doi: 10.1210/clinem/dgaf392. J Clin Endocrinol Metab. 2026. PMID: 40632818 Free PMC article.

3

Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression.

Triolo TM, Sosenko JM, Cuthbertson D, Oram RA, Parikh HM, Steck AK, Sims EK, Jacobsen LM, Nathan B, Templeman EL, Onengut-Gumuscu S, Evans-Molina C, Rich SS, Atkinson MA, Redondo MJ; Type 1 Diabetes TrialNet Study Group*. Triolo TM, et al. Diabetes. 2026 Jan 20;75(2):389-397. doi: 10.2337/db25-0711. Diabetes. 2026. PMID: 41369591 Free PMC article.

4

Baseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 Diabetes.

Galderisi A, Carr ALJ, Taylor P, Bonet J, Cuthbertson D, Sosenko J, Sims EK, Evans-Molina C, Dalla Man C, Ismail HM, Nathan B, Petrelli A, Senior P, Sherr JL, Herold KC, Russell WE, Moran A, Dayan C. Galderisi A, et al. Diabetes. 2026 Jan 20;75(2):229-240. doi: 10.2337/db25-0801. Diabetes. 2026. PMID: 41237315 Free PMC article. Clinical Trial.

5

Evaluation of proinsulin(F25D) as a targeting ligand for insulin-binding B cells in autoimmune diabetes.

Apley KD, Bass LE, King J, Downes G, Wang K, Forchetti MV, Moore DJ, Kendall P, Bonami RH, Berkland CJ. Apley KD, et al. Drug Deliv Transl Res. 2026 Jan;16(1):303-315. doi: 10.1007/s13346-025-01869-x. Epub 2025 May 22. Drug Deliv Transl Res. 2026. PMID: 40402465 Free PMC article.

6

Circulating senescence-associated secretory phenotype factors across the stages of type 1 diabetes in a cross-sectional cohort.

Préfontaine C, Pipella J, Heidinger I, Alcasid N, Thompson PJ. Préfontaine C, et al. Sci Rep. 2025 Nov 19;15(1):40845. doi: 10.1038/s41598-025-24506-6. Sci Rep. 2025. PMID: 41258222 Free PMC article.

7

Stage 1 type 1 diabetes memory B lymphocytes transcriptionally differ from healthy controls and harbor insulin-binding specificities.

Bass LE, McDonnell WJ, Brannon CT, Kumar NP, Mallal SA, Georgiev IS, Thomas JW, Moore DJ, Bonami RH. Bass LE, et al. Immunohorizons. 2025 Nov 9;9(11):vlaf053. doi: 10.1093/immhor/vlaf053. Immunohorizons. 2025. PMID: 41259806 Free PMC article.

8

Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.

Sims EK, Russell WE, Cuthbertson D, Skyler JS, Jacobsen LM, Ismail HM, Redondo MJ, Nathan BM, Carr ALJ, Taylor PN, Dayan CM, Galderisi A, Herold KC, Sosenko JM. Sims EK, et al. Diabetes. 2025 Nov 1;74(11):2101-2110. doi: 10.2337/db25-0310. Diabetes. 2025. PMID: 40877213 Free PMC article. Clinical Trial.

9

Metabolic Phenotype of Stage 1 and Stage 2 Type 1 Diabetes Using Modeling of β Cell Function.

Galderisi A, Bonet J, Ismail HM, Moran A, Fiorina P, Bosi E, Petrelli A. Galderisi A, et al. J Clin Endocrinol Metab. 2025 Oct 16;110(11):3168-3178. doi: 10.1210/clinem/dgaf086. J Clin Endocrinol Metab. 2025. PMID: 39992257 Free PMC article.

10

Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study.

Templeman EL, Ferrat LA, Thomas N, Speake C, Wherrett DK, Sherr J, Wentworth JM, Redondo MJ, Parik HM, Felton JL, Evans-Molina C, Sosenko J, You L, Oram RA, Sims EK. Templeman EL, et al. Diabetes Care. 2025 Sep 1;48(9):1571-1580. doi: 10.2337/dc25-0192. Diabetes Care. 2025. PMID: 40694568

11

M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-term Response to Preventive Immunotherapy.

Le MV, Harrison LC, Spelman T, Wentworth JM. Le MV, et al. Diabetes Care. 2025 Aug 1;48(8):1352-1355. doi: 10.2337/dc24-2794. Diabetes Care. 2025. PMID: 40208750 Free PMC article.

12

Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies.

Templeman EL, Ferrat LA, Parikh HM, You L, Triolo TM, Steck AK, Hagopian WA, Vehik K, Onengut-Gumuscu S, Gottlieb PA, Rich SS, Krischer JP, Redondo MJ, Oram RA; Type 1 diabetes TrialNet Study Group. Templeman EL, et al. BMC Med. 2025 Jul 21;23(1):433. doi: 10.1186/s12916-025-04225-5. BMC Med. 2025. PMID: 40691800 Free PMC article.

13

Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding.

Jacobsen LM, Felton JL, Nathan BM, Speake C, Krischer J, Herold KC. Jacobsen LM, et al. Diabetes Care. 2025 Jul 1;48(7):1112-1124. doi: 10.2337/dc24-2908. Diabetes Care. 2025. PMID: 40272284 Free PMC article. Review.

14

The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes.

Ismail HM, Cuthbertson D, Galderisi A, Libman I, Jacobsen L, Moran A, Petrelli A, Atkinson M, Redondo MJ, Hannon T, Mather KJ, Sosenko JM. Ismail HM, et al. Diabetes. 2025 Jul 1;74(7):1196-1204. doi: 10.2337/db24-1000. Diabetes. 2025. PMID: 40173211 Free PMC article.

15

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.

Sims EK, Cuthbertson D, Ferrat LA, Bosi E, Evans-Molina C, DiMeglio LA, Nathan BM, Ismail HM, Jacobsen LM, Redondo MJ, Oram RA, Sosenko JM. Sims EK, et al. Diabetologia. 2025 May;68(5):993-1004. doi: 10.1007/s00125-025-06382-x. Epub 2025 Feb 28. Diabetologia. 2025. PMID: 40016443 Free PMC article.

16

Activated polyreactive B cells are clonally expanded in autoantibody positive and patients with recent-onset type 1 diabetes.

Nicholas CA, Tensun FA, Evans SA, Toole KP, Prendergast JE, Broncucia H, Hesselberth JR, Gottlieb PA, Wells KL, Smith MJ. Nicholas CA, et al. Cell Rep. 2025 Apr 22;44(4):115425. doi: 10.1016/j.celrep.2025.115425. Epub 2025 Mar 19. Cell Rep. 2025. PMID: 40117290 Free PMC article.

17

Enhancing Type 1 Diabetes Immunological Risk Prediction with Continuous Glucose Monitoring and Genetic Profiling.

Montaser E, Farhy LS, Rich SS. Montaser E, et al. Diabetes Technol Ther. 2025 Apr;27(4):292-300. doi: 10.1089/dia.2024.0496. Epub 2024 Dec 17. Diabetes Technol Ther. 2025. PMID: 39686752 Free PMC article.

18

Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives.

Triolo TM, Parikh HM, Tosur M, Ferrat LA, You L, Gottlieb PA, Oram RA, Onengut-Gumuscu S, Krischer JP, Rich SS, Steck AK, Redondo MJ. Triolo TM, et al. J Clin Endocrinol Metab. 2025 Mar 17;110(4):e1046-e1050. doi: 10.1210/clinem/dgae349. J Clin Endocrinol Metab. 2025. PMID: 38767115 Free PMC article.

19

A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts.

Sosenko JM, Cuthbertson D, Jacobsen LM, Redondo MJ, Sims EK, Ismail HM, Herold KC, Skyler JS, Nathan BM; DPT-1 and TrialNet Study Groups. Sosenko JM, et al. Diabetes Technol Ther. 2025 Mar;27(3):179-186. doi: 10.1089/dia.2024.0422. Epub 2025 Jan 6. Diabetes Technol Ther. 2025. PMID: 39757867 Free PMC article.

20

Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.

Galderisi A, Sims EK, Evans-Molina C, Petrelli A, Cuthbertson D, Nathan BM, Ismail HM, Herold KC, Moran A. Galderisi A, et al. Diabetologia. 2025 Mar;68(3):646-661. doi: 10.1007/s00125-024-06323-0. Epub 2024 Nov 19. Diabetologia. 2025. PMID: 39560746 Free PMC article. Clinical Trial.

21

A type 1 diabetes prediction model has utility across multiple screening settings with recalibration.

Templeman EL, Ferrat LA, Parikh HM, You L, Triolo TM, Steck AK, Hagopian WA, Vehik K, Onengut-Gumuscu S, Gottlieb PA, Rich SS, Krischer JP, Redondo MJ, Oram RA; Type 1 diabetes TrialNet Study Group. Templeman EL, et al. Res Sq [Preprint]. 2025 Feb 6:rs.3.rs-5773430. doi: 10.21203/rs.3.rs-5773430/v1. Res Sq. 2025. Update in: BMC Med. 2025 Jul 21;23(1):433. doi: 10.1186/s12916-025-04225-5. PMID: 39975907 Free PMC article. Updated. Preprint.

22

Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes.

Pribitzer S, O'Rourke C, Ylescupidez A, Smithmyer M, Bender C, Speake C, Lord S, Greenbaum CJ. Pribitzer S, et al. J Clin Endocrinol Metab. 2024 Nov 18;109(12):3211-3219. doi: 10.1210/clinem/dgae292. J Clin Endocrinol Metab. 2024. PMID: 38712386 Free PMC article.

23

Evolving Concepts in Pathophysiology, Screening, and Prevention of Type 1 Diabetes: Report of Diabetes Mellitus Interagency Coordinating Committee Workshop.

Greenbaum CJ, Nepom GT, Wood-Heickman LK, Wherrett DK, DiMeglio LA, Herold KC, Krischer JP. Greenbaum CJ, et al. Diabetes. 2024 Nov 1;73(11):1780-1790. doi: 10.2337/dbi24-0020. Diabetes. 2024. PMID: 39167668 Free PMC article. Review.

24

Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis.

You L, Ferrat LA, Oram RA, Parikh HM, Steck AK, Krischer J, Redondo MJ; Type 1 Diabetes TrialNet Study Group. You L, et al. Diabetologia. 2024 Nov;67(11):2507-2517. doi: 10.1007/s00125-024-06246-w. Epub 2024 Aug 6. Diabetologia. 2024. PMID: 39103721 Free PMC article.

25

Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.

Sims EK, Cuthbertson D, Jacobsen L, Ismail HM, Nathan BM, Herold KC, Redondo MJ, Sosenko J. Sims EK, et al. J Clin Endocrinol Metab. 2024 Jul 12;109(8):2116-2123. doi: 10.1210/clinem/dgae048. J Clin Endocrinol Metab. 2024. PMID: 38267821 Free PMC article. Clinical Trial.

26

Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.

Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM; Type 1 Diabetes TrialNet Study Group. Jacobsen LM, et al. Diabetes Care. 2024 Jun 1;47(6):1048-1055. doi: 10.2337/dc24-0171. Diabetes Care. 2024. PMID: 38621411 Free PMC article.

27

High proinsulin:C-peptide ratio identifies individuals with stage 2 type 1 diabetes at high risk for progression to clinical diagnosis and responses to teplizumab treatment.

Sims EK, Geyer SM, Long SA, Herold KC. Sims EK, et al. Diabetologia. 2023 Dec;66(12):2283-2291. doi: 10.1007/s00125-023-06003-5. Epub 2023 Sep 4. Diabetologia. 2023. PMID: 37667106 Free PMC article.

28

A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.

Ylescupidez A, Bahnson HT, O'Rourke C, Lord S, Speake C, Greenbaum CJ. Ylescupidez A, et al. Nat Commun. 2023 Nov 8;14(1):7214. doi: 10.1038/s41467-023-42581-z. Nat Commun. 2023. PMID: 37940642 Free PMC article.

29

Response to Comment on Russell et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023;46:1005-1013.

Russell WE, Moore DJ, Herold KC. Russell WE, et al. Diabetes Care. 2023 Nov 1;46(11):e210-e211. doi: 10.2337/dci23-0050. Diabetes Care. 2023. PMID: 37890101 Free PMC article. No abstract available.

30

Hydroxychloroquine in Stage 1 Type 1 Diabetes.

Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC; Type 1 Diabetes TrialNet Study Group. Libman I, et al. Diabetes Care. 2023 Nov 1;46(11):2035-2043. doi: 10.2337/dc23-1096. Diabetes Care. 2023. PMID: 37708415 Free PMC article.

31

Type 1 Diabetes Risk Phenotypes Using Cluster Analysis.

You L, Ferrat LA, Oram RA, Parikh HM, Steck AK, Krischer J, Redondo MJ; Type 1 Diabetes TrialNet Study Group. You L, et al. medRxiv [Preprint]. 2023 Oct 12:2023.10.10.23296375. doi: 10.1101/2023.10.10.23296375. medRxiv. 2023. Update in: Diabetologia. 2024 Nov;67(11):2507-2517. doi: 10.1007/s00125-024-06246-w. PMID: 37873281 Free PMC article. Updated. Preprint.

32

Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies.

Sosenko JM, Cuthbertson D, Sims EK, Ismail HM, Nathan BM, Jacobsen LM, Atkinson MA, Evans-Molina C, Herold KC, Skyler JS, Redondo MJ; TrialNet Study Group. Sosenko JM, et al. Diabetes Care. 2023 May 1;46(5):1098-1105. doi: 10.2337/dc22-2236. Diabetes Care. 2023. PMID: 37000695 Free PMC article.

33

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.

Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC; Type 1 Diabetes TrialNet Study Group. Russell WE, et al. Diabetes Care. 2023 May 1;46(5):1005-1013. doi: 10.2337/dc22-2200. Diabetes Care. 2023. PMID: 36920087 Free PMC article. Clinical Trial.

34

Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening.

Sims EK, Cuthbertson D, Felton JL, Ismail HM, Nathan BM, Jacobsen LM, Paprocki E, Pugliese A, Palmer J, Atkinson M, Evans-Molina C, Skyler JS, Redondo MJ, Herold KC, Sosenko JM. Sims EK, et al. Diabetes Care. 2022 Dec 1;45(12):2982-2990. doi: 10.2337/dc22-1362. Diabetes Care. 2022. PMID: 36326757 Free PMC article.

35

Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand.

Wentworth JM, Oakey H, Craig ME, Couper JJ, Cameron FJ, Davis EA, Lafferty AR, Harris M, Wheeler BJ, Jefferies C, Colman PG, Harrison LC. Wentworth JM, et al. Pediatr Diabetes. 2022 Dec;23(8):1594-1601. doi: 10.1111/pedi.13422. Epub 2022 Oct 7. Pediatr Diabetes. 2022. PMID: 36175392 Free PMC article.

36

The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk.

Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J; DPT-1 and TrialNet Study Groups. Ismail HM, et al. Diabetes Care. 2022 Oct 1;45(10):2264-2270. doi: 10.2337/dc22-0167. Diabetes Care. 2022. PMID: 35998266 Free PMC article.

37

Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.

Jacobsen LM, Bundy BN, Ismail HM, Clements M, Warnock M, Geyer S, Schatz DA, Sosenko JM. Jacobsen LM, et al. J Clin Endocrinol Metab. 2022 Sep 28;107(10):2784-2792. doi: 10.1210/clinem/dgac440. J Clin Endocrinol Metab. 2022. PMID: 35880956 Free PMC article.

38

Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.

Baidal DA, Warnock M, Xu P, Geyer S, Marks JB, Moran A, Sosenko J, Evans-Molina C. Baidal DA, et al. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3273-e3280. doi: 10.1210/clinem/dgac285. J Clin Endocrinol Metab. 2022. PMID: 35524749 Free PMC article.

39

Characterising the age-dependent effects of risk factors on type 1 diabetes progression.

So M, O'Rourke C, Ylescupidez A, Bahnson HT, Steck AK, Wentworth JM, Bruggeman BS, Lord S, Greenbaum CJ, Speake C. So M, et al. Diabetologia. 2022 Apr;65(4):684-694. doi: 10.1007/s00125-021-05647-5. Epub 2022 Jan 18. Diabetologia. 2022. PMID: 35041021 Free PMC article.

40

Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes.

Nathan BM, Redondo MJ, Ismail H, Jacobsen L, Sims EK, Palmer J, Skyler J, Bocchino L, Geyer S, Sosenko JM. Nathan BM, et al. Diabetes Care. 2022 Feb 1;45(2):311-318. doi: 10.2337/dc21-0944. Diabetes Care. 2022. PMID: 34853027 Free PMC article.

41

HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants.

Felton JL, Cuthbertson D, Warnock M, Lohano K, Meah F, Wentworth JM, Sosenko J, Evans-Molina C; Type 1 Diabetes TrialNet Study Group. Felton JL, et al. Diabetologia. 2022 Jan;65(1):88-100. doi: 10.1007/s00125-021-05573-6. Epub 2021 Oct 12. Diabetologia. 2022. PMID: 34642772 Free PMC article.

42

The Deterrence of Rapid Metabolic Decline Within 3 Months After Teplizumab Treatment in Individuals at High Risk for Type 1 Diabetes.

Sims EK, Cuthbertson D, Herold KC, Sosenko JM. Sims EK, et al. Diabetes. 2021 Dec;70(12):2922-2931. doi: 10.2337/db21-0519. Epub 2021 Sep 22. Diabetes. 2021. PMID: 34551936 Free PMC article. Clinical Trial.

43

Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM. Bediaga NG, et al. Diabetologia. 2021 Nov;64(11):2432-2444. doi: 10.1007/s00125-021-05523-2. Epub 2021 Aug 2. Diabetologia. 2021. PMID: 34338806 Free PMC article.

44

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.

Voss MG, Cuthbertson DD, Cleves MM, Xu P, Evans-Molina C, Palmer JP, Redondo MJ, Steck AK, Lundgren M, Larsson H, Moore WV, Atkinson MA, Sosenko JM, Ismail HM; DPT-1 and TrialNet Study Groups. Voss MG, et al. Diabetes Care. 2021 Oct;44(10):2329-2336. doi: 10.2337/dc21-0226. Epub 2021 Aug 6. Diabetes Care. 2021. PMID: 34362815 Free PMC article. Clinical Trial.

45

TCF7L2 Genetic Variants Do Not Influence Insulin Sensitivity or Secretion Indices in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes.

Redondo MJ, Warnock MV, Libman IM, Bocchino LE, Cuthbertson D, Geyer S, Pugliese A, Steck AK, Evans-Molina C, Becker D, Sosenko JM, Bacha F; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2021 Sep;44(9):2039-2044. doi: 10.2337/dc21-0531. Epub 2021 Jul 29. Diabetes Care. 2021. PMID: 34326068 Free PMC article.

46

Index60 as an additional diagnostic criterion for type 1 diabetes.

Redondo MJ, Nathan BM, Jacobsen LM, Sims E, Bocchino LE, Pugliese A, Schatz DA, Atkinson MA, Skyler J, Palmer J, Geyer S, Sosenko JM; Type 1 diabetes TrialNet Study Group. Redondo MJ, et al. Diabetologia. 2021 Apr;64(4):836-844. doi: 10.1007/s00125-020-05365-4. Epub 2021 Jan 26. Diabetologia. 2021. PMID: 33496819 Free PMC article.

47

Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.

Ross JJ, Wasserfall CH, Bacher R, Perry DJ, McGrail K, Posgai AL, Dong X, Muir A, Li X, Campbell-Thompson M, Brusko TM, Schatz DA, Haller MJ, Atkinson MA. Ross JJ, et al. Diabetes. 2021 Apr;70(4):944-954. doi: 10.2337/db20-0995. Epub 2021 Jan 13. Diabetes. 2021. PMID: 33441381 Free PMC article.

48

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.

Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980. Sci Transl Med. 2021. PMID: 33658358 Free PMC article. Clinical Trial.

49

Baseline Assessment of Circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion.

Snowhite I, Pastori R, Sosenko J, Messinger Cayetano S, Pugliese A. Snowhite I, et al. Diabetes. 2021 Feb;70(2):638-651. doi: 10.2337/db20-0817. Epub 2020 Dec 4. Diabetes. 2021. PMID: 33277338 Free PMC article.

50

Gene Expression Analysis of the Pre-Diabetic Pancreas to Identify Pathogenic Mechanisms and Biomarkers of Type 1 Diabetes.

Yip L, Fuhlbrigge R, Alkhataybeh R, Fathman CG. Yip L, et al. Front Endocrinol (Lausanne). 2020 Dec 23;11:609271. doi: 10.3389/fendo.2020.609271. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33424774 Free PMC article.

51

Exocrine Pancreas Dysfunction in Type 1 Diabetes.

Foster TP, Bruggeman B, Campbell-Thompson M, Atkinson MA, Haller MJ, Schatz DA. Foster TP, et al. Endocr Pract. 2020 Dec;26(12):1505-1513. doi: 10.4158/EP-2020-0295. Endocr Pract. 2020. PMID: 33471743 Free PMC article. Review.

52

Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes.

Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ. Jacobsen LM, et al. Diabetes Technol Ther. 2020 Dec;22(12):948-953. doi: 10.1089/dia.2020.0305. Epub 2020 Oct 20. Diabetes Technol Ther. 2020. PMID: 32833543 Free PMC article.

53

The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis.

Tosur M, Cleves MA, Sosenko JM, Libman I, Baidal DA, Balasubramanyam A, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Tosur M, et al. J Clin Endocrinol Metab. 2020 Dec 1;105(12):e4393-406. doi: 10.1210/clinem/dgaa348. J Clin Endocrinol Metab. 2020. PMID: 32502242 Free PMC article.

54

The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.

Ismail HM, Cleves MA, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Ismail HM, et al. Diabetes Care. 2020 Nov;43(11):2668-2674. doi: 10.2337/dc20-0701. Epub 2020 Sep 8. Diabetes Care. 2020. PMID: 32900788 Free PMC article.

55

Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. Diabetes Care 2020;43:913-917.

So M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C. So M, et al. Diabetes Care. 2020 Aug;43(8):e103-e104. doi: 10.2337/dci20-0016. Diabetes Care. 2020. PMID: 32669415 Free PMC article. No abstract available.

56

C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.

Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. Bogun MM, et al. Diabetes Care. 2020 Aug;43(8):1836-1842. doi: 10.2337/dc19-2288. Epub 2020 May 26. Diabetes Care. 2020. PMID: 32457058 Free PMC article.

57

Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic β cells.

Neiman D, Gillis D, Piyanzin S, Cohen D, Fridlich O, Moss J, Zick A, Oron T, Sundberg F, Forsander G, Skog O, Korsgren O, Levy-Khademi F, Arbel D, Hashavia S, Shapiro AMJ, Speake C, Greenbaum C, Hosford J, Posgai A, Atkinson MA, Glaser B, Schatz DA, Shemer R, Dor Y. Neiman D, et al. JCI Insight. 2020 Jul 23;5(14):e136579. doi: 10.1172/jci.insight.136579. JCI Insight. 2020. PMID: 32573495 Free PMC article.

58

A quantitative measure of treatment response in recent-onset type 1 diabetes.

Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group. Bundy BN, et al. Endocrinol Diabetes Metab. 2020 May 14;3(3):e00143. doi: 10.1002/edm2.143. eCollection 2020 Jul. Endocrinol Diabetes Metab. 2020. PMID: 32704564 Free PMC article.

59

Costimulation Blockade Disrupts CD4⁺ T Cell Memory Pathways and Uncouples Their Link to Decline in β-Cell Function in Type 1 Diabetes.

Eichmann M, Baptista R, Ellis RJ, Heck S, Peakman M, Beam CA. Eichmann M, et al. J Immunol. 2020 Jun 15;204(12):3129-3138. doi: 10.4049/jimmunol.1901439. Epub 2020 May 13. J Immunol. 2020. PMID: 32404353 Free PMC article.

60

Early and late C-peptide responses during oral glucose tolerance testing are oppositely predictive of type 1 diabetes in autoantibody-positive individuals.

Ismail HM, Becker DJ, Libman I, Herold KC, Redondo MJ, Atkinson MA, Cleves MA, Palmer J, Sosenko J; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group. Ismail HM, et al. Diabetes Obes Metab. 2020 Jun;22(6):997-1000. doi: 10.1111/dom.13982. Epub 2020 Feb 27. Diabetes Obes Metab. 2020. PMID: 32003110 Free PMC article.

61

Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance.

Redondo MJ, Sosenko J, Libman I, McVean JJF, Tosur M, Atkinson MA, Becker D, Geyer S. Redondo MJ, et al. J Clin Endocrinol Metab. 2020 May 1;105(5):1629-40. doi: 10.1210/clinem/dgz296. J Clin Endocrinol Metab. 2020. PMID: 31867614 Free PMC article.

62

Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals.

So M, O'Rourke C, Bahnson HT, Greenbaum CJ, Speake C. So M, et al. Diabetes Care. 2020 Apr;43(4):913-917. doi: 10.2337/dc19-1731. Epub 2020 Feb 4. Diabetes Care. 2020. PMID: 32019856 Free PMC article.

63

Clinical trial data validate the C-peptide estimate model in type 1 diabetes.

Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. Wentworth JM, et al. Diabetologia. 2020 Apr;63(4):885-886. doi: 10.1007/s00125-020-05088-6. Epub 2020 Jan 26. Diabetologia. 2020. PMID: 31982961 Free PMC article. No abstract available.

64

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.

Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Ferrara-Cook C, et al. Diabetes Care. 2020 Mar;43(3):580-587. doi: 10.2337/dc19-1167. Epub 2020 Jan 14. Diabetes Care. 2020. PMID: 31937610 Free PMC article.

65

The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.

Jacobsen LM, Bocchino L, Evans-Molina C, DiMeglio L, Goland R, Wilson DM, Atkinson MA, Aye T, Russell WE, Wentworth JM, Boulware D, Geyer S, Sosenko JM. Jacobsen LM, et al. Diabetologia. 2020 Mar;63(3):588-596. doi: 10.1007/s00125-019-05047-w. Epub 2019 Nov 25. Diabetologia. 2020. PMID: 31768570 Free PMC article.

66

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.

Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D, Rafkin LE, Matheson D, Atkinson MA, Rodriguez H, Spall M, Elding Larsson H, Wherrett DK, Greenbaum CJ, Krischer J, DiMeglio LA; Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Diabetes Care. 2019 Dec;42(12):2228-2236. doi: 10.2337/dc19-0593. Epub 2019 Sep 26. Diabetes Care. 2019. PMID: 31558546 Free PMC article.

67

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes.

Acevedo-Calado MJ, Pietropaolo SL, Morran MP, Schnell S, Vonberg AD, Verge CF, Gianani R, Becker DJ, Huang S, Greenbaum CJ, Yu L, Davidson HW, Michels AW, Rich SS, Pietropaolo M; Type 1 Diabetes TrialNet Study Group. Acevedo-Calado MJ, et al. Diabetes. 2019 Sep;68(9):1819-1829. doi: 10.2337/db18-1351. Epub 2019 Jun 5. Diabetes. 2019. PMID: 31167877 Free PMC article.

68

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.

69

Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression.

Habib T, Long SA, Samuels PL, Brahmandam A, Tatum M, Funk A, Hocking AM, Cerosaletti K, Mason MT, Whalen E, Rawlings DJ, Greenbaum C, Buckner JH; Type 1 Diabetes TrialNet Study Group. Habib T, et al. Diabetes. 2019 Jun;68(6):1240-1250. doi: 10.2337/db18-1081. Epub 2019 Mar 20. Diabetes. 2019. PMID: 30894366 Free PMC article.

70

Associations of HbA1c with the timing of C-peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes.

Ismail HM, Evans-Molina C, DiMeglio LA, Becker DJ, Libman I, Sims EK, Boulware D, Herold KC, Rafkin L, Skyler J, Cleves MA, Palmer J, Sosenko JM; Type 1 Diabetes Trial Net and Diabetes Prevention Trial-Type-1 (DPT-1) Study Groups. Ismail HM, et al. Pediatr Diabetes. 2019 Jun;20(4):408-413. doi: 10.1111/pedi.12845. Epub 2019 Apr 15. Pediatr Diabetes. 2019. PMID: 30891858 Free PMC article.

71

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ. Linsley PS, et al. Genes Immun. 2019 Apr;20(4):293-307. doi: 10.1038/s41435-018-0032-1. Epub 2018 Jun 21. Genes Immun. 2019. PMID: 29925930 Free PMC article. Clinical Trial.

72

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ. Linsley PS, et al. JCI Insight. 2019 Feb 21;4(4):e126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830871 Free PMC article.

73

Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.

Dufort MJ, Greenbaum CJ, Speake C, Linsley PS. Dufort MJ, et al. JCI Insight. 2019 Feb 21;4(4):e125556. doi: 10.1172/jci.insight.125556. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830868 Free PMC article.

74

A novel platform for isotype-specific testing of autoantibodies.

Carter KL, Treurnicht A, Davis KL, Kumar RB, Feldman BJ. Carter KL, et al. PLoS One. 2019 Feb 7;14(2):e0211596. doi: 10.1371/journal.pone.0211596. eCollection 2019. PLoS One. 2019. PMID: 30730939 Free PMC article.

75

Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children.

Paun A, Yau C, Meshkibaf S, Daigneault MC, Marandi L, Mortin-Toth S, Bar-Or A, Allen-Vercoe E, Poussier P, Danska JS. Paun A, et al. Sci Immunol. 2019 Feb 1;4(32):eaau8125. doi: 10.1126/sciimmunol.aau8125. Sci Immunol. 2019. PMID: 30709843 Free PMC article.

76

Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes.

Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH, Gurka MJ, Atkinson MA, Schatz DA, Haller MJ. Campbell-Thompson ML, et al. Diabetes Care. 2019 Feb;42(2):281-287. doi: 10.2337/dc18-1512. Epub 2018 Dec 14. Diabetes Care. 2019. PMID: 30552130 Free PMC article.

77

Analysis of serum Hsp90 as a potential biomarker of β cell autoimmunity in type 1 diabetes.

Ocaña GJ, Sims EK, Watkins RA, Ragg S, Mather KJ, Oram RA, Mirmira RG, DiMeglio LA, Blum JS, Evans-Molina C. Ocaña GJ, et al. PLoS One. 2019 Jan 10;14(1):e0208456. doi: 10.1371/journal.pone.0208456. eCollection 2019. PLoS One. 2019. PMID: 30629603 Free PMC article.

78

FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer.

Pan MR, Hou MF, Ou-Yang F, Wu CC, Chang SJ, Hung WC, Yip HK, Luo CW. Pan MR, et al. J Clin Med. 2019 Jan 2;8(1):38. doi: 10.3390/jcm8010038. J Clin Med. 2019. PMID: 30609732 Free PMC article.

79

Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables.

Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC; Type 1 Diabetes TrialNet Study Group; Immune Tolerance Network Study Group. Wentworth JM, et al. Diabetologia. 2019 Jan;62(1):33-40. doi: 10.1007/s00125-018-4722-z. Epub 2018 Aug 30. Diabetologia. 2019. PMID: 30167735 Free PMC article. Review.

80

Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes.

Redondo MJ, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth JM, Atkinson MA, Pugliese A, Geyer S; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2018 Dec;41(12):2480-2486. doi: 10.2337/dc18-0861. Epub 2018 Oct 1. Diabetes Care. 2018. PMID: 30275285 Free PMC article.

81

From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis.

Wang HC, Hung WC, Chen LT, Pan MR. Wang HC, et al. Int J Mol Sci. 2018 Nov 13;19(11):3584. doi: 10.3390/ijms19113584. Int J Mol Sci. 2018. PMID: 30428588 Free PMC article. Review.

82

Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes.

Harms RZ, Lorenzo-Arteaga KM, Ostlund KR, Smith VB, Smith LM, Gottlieb P, Sarvetnick N. Harms RZ, et al. Front Immunol. 2018 Oct 22;9:2332. doi: 10.3389/fimmu.2018.02332. eCollection 2018. Front Immunol. 2018. PMID: 30405601 Free PMC article.

83

Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes.

Vecchio F, Lo Buono N, Stabilini A, Nigi L, Dufort MJ, Geyer S, Rancoita PM, Cugnata F, Mandelli A, Valle A, Leete P, Mancarella F, Linsley PS, Krogvold L, Herold KC, Elding Larsson H, Richardson SJ, Morgan NG, Dahl-Jørgensen K, Sebastiani G, Dotta F, Bosi E; DRI_Biorepository Group; Type 1 Diabetes TrialNet Study Group; Battaglia M. Vecchio F, et al. JCI Insight. 2018 Sep 20;3(18):e122146. doi: 10.1172/jci.insight.122146. eCollection 2018 Sep 20. JCI Insight. 2018. PMID: 30232284 Free PMC article.

84

Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.

Tian YF, Wang HC, Luo CW, Hung WC, Lin YH, Chen TY, Li CF, Lin CY, Pan MR. Tian YF, et al. Am J Cancer Res. 2018 Sep 1;8(9):1812-1822. eCollection 2018. Am J Cancer Res. 2018. PMID: 30323973 Free PMC article.

85

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk.

Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P, Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2018 Sep;41(9):1887-1894. doi: 10.2337/dc18-0087. Epub 2018 Jul 12. Diabetes Care. 2018. PMID: 30002199 Free PMC article.

86

Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.

Tosur M, Geyer SM, Rodriguez H, Libman I, Baidal DA, Redondo MJ; Type 1 Diabetes TrialNet Study Group. Tosur M, et al. Diabetologia. 2018 Sep;61(9):2043-2053. doi: 10.1007/s00125-018-4660-9. Epub 2018 Jun 21. Diabetologia. 2018. PMID: 29931415 Free PMC article.

87

β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.

Evans-Molina C, Sims EK, DiMeglio LA, Ismail HM, Steck AK, Palmer JP, Krischer JP, Geyer S, Xu P, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Evans-Molina C, et al. JCI Insight. 2018 Aug 9;3(15):e120877. doi: 10.1172/jci.insight.120877. eCollection 2018 Aug 9. JCI Insight. 2018. PMID: 30089716 Free PMC article.

88

Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Yeo L, Woodwyk A, Sood S, Lorenc A, Eichmann M, Pujol-Autonell I, Melchiotti R, Skowera A, Fidanis E, Dolton GM, Tungatt K, Sewell AK, Heck S, Saxena A, Beam CA, Peakman M. Yeo L, et al. J Clin Invest. 2018 Aug 1;128(8):3460-3474. doi: 10.1172/JCI120555. Epub 2018 Jul 16. J Clin Invest. 2018. PMID: 29851415 Free PMC article. Clinical Trial.

89

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA. Greenbaum CJ, et al. Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16. Diabetes. 2018. PMID: 29769238 Free PMC article.

90

The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1.

Sosenko JM, Geyer S, Skyler JS, Rafkin LE, Ismail HM, Libman IM, Liu YF, DiMeglio LA, Evans-Molina C, Palmer JP. Sosenko JM, et al. Pediatr Diabetes. 2018 May;19(3):403-409. doi: 10.1111/pedi.12609. Epub 2017 Nov 24. Pediatr Diabetes. 2018. PMID: 29171129 Free PMC article. Clinical Trial.

91

Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests.

Sanda S; Type 1 Diabetes TrialNet Study Group. Sanda S, et al. Pediatr Diabetes. 2018 Mar;19(2):271-276. doi: 10.1111/pedi.12542. Epub 2017 Jul 14. Pediatr Diabetes. 2018. PMID: 28707353 Free PMC article.

92

TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes.

Redondo MJ, Geyer S, Steck AK, Sosenko J, Anderson M, Antinozzi P, Michels A, Wentworth J, Xu P, Pugliese A; Type 1 Diabetes TrialNet Study Group. Redondo MJ, et al. Diabetes Care. 2018 Feb;41(2):311-317. doi: 10.2337/dc17-0961. Epub 2017 Oct 12. Diabetes Care. 2018. PMID: 29025879 Free PMC article.

93

The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.

Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Ismail HM, et al. Diabetologia. 2018 Jan;61(1):84-92. doi: 10.1007/s00125-017-4453-6. Epub 2017 Sep 27. Diabetologia. 2018. PMID: 28956083 Free PMC article.

94

Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Hao W, Woodwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ. Hao W, et al. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4428-4434. doi: 10.1210/jc.2017-01713. J Clin Endocrinol Metab. 2017. PMID: 29040630 Free PMC article.

95

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.

Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group; Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, et al. JAMA. 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070. JAMA. 2017. PMID: 29164254 Free PMC article. Clinical Trial.

96

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Nathan BM, Boulware D, Geyer S, Atkinson MA, Colman P, Goland R, Russell W, Wentworth JM, Wilson DM, Evans-Molina C, Wherrett D, Skyler JS, Moran A, Sosenko JM; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Nathan BM, et al. Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31. Diabetes Care. 2017. PMID: 28860125 Free PMC article.

97

Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M. Battaglia M, et al. Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Diabetologia. 2017. PMID: 28770323 Free PMC article. Review.

98

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Bosi E, et al. J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569. J Clin Endocrinol Metab. 2017. PMID: 28531305 Free PMC article.

99

Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes.

Snowhite IV, Allende G, Sosenko J, Pastori RL, Messinger Cayetano S, Pugliese A. Snowhite IV, et al. Diabetologia. 2017 Aug;60(8):1409-1422. doi: 10.1007/s00125-017-4294-3. Epub 2017 May 12. Diabetologia. 2017. PMID: 28500393 Free PMC article.

100

Use of self-collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study.

Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group. Liu Y, et al. Diabet Med. 2017 Jul;34(7):934-937. doi: 10.1111/dme.13338. Epub 2017 Mar 8. Diabet Med. 2017. PMID: 28226181 Free PMC article.

101

GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.

Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1 Diabetes TrialNet Study Group. Beam CA, et al. Diabetologia. 2017 Jan;60(1):43-49. doi: 10.1007/s00125-016-4122-1. Epub 2016 Oct 4. Diabetologia. 2017. PMID: 27704166 Free PMC article.

102

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.

Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko JM; Type 1 Diabetes TrialNet Study Group. Pugliese A, et al. Diabetes. 2016 Apr;65(4):1109-19. doi: 10.2337/db15-1105. Epub 2016 Jan 28. Diabetes. 2016. PMID: 26822082 Free PMC article.

103

The implications of autoantibodies to a single islet antigen in relatives with normal glucose tolerance: development of other autoantibodies and progression to type 1 diabetes.

Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group. Bingley PJ, et al. Diabetologia. 2016 Mar;59(3):542-9. doi: 10.1007/s00125-015-3830-2. Epub 2015 Dec 16. Diabetologia. 2016. PMID: 26676824 Free PMC article.

104

Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study.

Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware DC; TrialNet Study Group. Bingley PJ, et al. Diabetes Technol Ther. 2015 Dec;17(12):867-71. doi: 10.1089/dia.2015.0133. Epub 2015 Sep 16. Diabetes Technol Ther. 2015. PMID: 26375197 Free PMC article.

105

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Wherrett DK, et al. Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Diabetes Care. 2015. PMID: 26404927 Free PMC article. Review.

106

Screening and Monitoring for Infectious Complications When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders.

Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR; Type 1 Diabetes TrialNet Study Group. Loechelt BJ, et al. J Pediatric Infect Dis Soc. 2015 Sep;4(3):198-204. doi: 10.1093/jpids/piu055. Epub 2014 Jun 26. J Pediatric Infect Dis Soc. 2015. PMID: 26336066 Free PMC article.

107

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10. Diabetes Care. 2015. PMID: 25758770 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Results by year